Roger Pomerantz, ContraFect CEO (via X-Vax)
July 14, 2022 10:47 AM EDTUpdated 11:05 AM
R&D

Up­dat­ed: Con­tra­Fect to ter­mi­nate PhI­II MR­SA an­tibi­ot­ic tri­al — stock cap­sizes

Lei Lei Wu

News Reporter

One year af­ter BAR­DA backed Con­tra­Fect’s MR­SA treat­ment, the Yonkers, NY-based biotech said Wednes­day it will stop its Phase III tri­al of the as­set ear­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times